Discovery of a Highly Specific F-labeled PET Ligand for Phosphodiesterase 10A Enabled by Novel Spirocyclic Iodonium Ylide Radiofluorination

As a member of cyclic nucleotide phosphodiesterase (PDE) enzyme family, PDE10A is in charge of the degradation of cyclic adenosine (cAMP) and guanosine monophosphates (cGMP). While PDE10A is primarily expressed in the medium spiny neurons of the striatum, it has been implicated in a variety of neurological disorders. Indeed, inhibition of PDE10A has proven to be of potential use for the treatment of central nervous system (CNS) pathologies caused by dysfunction of the basal ganglia-of which the striatum constitutes the largest component. A PDE10A-targeted positron emission tomography (PET) radioligand would enable a better assessment of the pathophysiologic role of PDE10A, as well as confirm the relationship between target occupancy and administrated dose of a given drug candidate, thus accelerating the development of effective PDE10A inhibitors. In this study, we designed and synthesized a novel F-aryl PDE10A PET radioligand, codenamed [F]P10A-1910 ([F]), in high radiochemical yield and molar activity spirocyclic iodonium ylide-mediated radiofluorination. [F] possessed good binding affinity (IC = 2.1 nmol/L) and selectivity towards PDE10A. Further, [F] exhibited reasonable lipophilicity (log = 3.50) and brain permeability (  > 10 × 10 cm/s in MDCK-MDR1 cells). PET imaging studies of [F] revealed high striatal uptake and excellent specificity with reversible tracer kinetics. Preclinical studies in rodents revealed an improved plasma and brain stability of [F] when compared to the current reference standard for PDE10A-targeted PET, [F]MNI659. Further, dose-response experiments with a series of escalating doses of PDE10A inhibitor in rhesus monkey brains confirmed the utility of [F] for evaluating target occupancy in higher species. In conclusion, our results indicated that [F] is a promising PDE10A PET radioligand for clinical translation.